Can a triple punch of immunotherapy and chemoradiation wipe out esophageal tumors before surgery?
NCT ID NCT07751055
First seen Aug 07, 2026 · Last updated Aug 07, 2026
Summary
This trial is testing whether giving a combination of two immunotherapies (ipilimumab and sintilimab) along with chemotherapy and radiation before surgery can completely eliminate cancer cells in people with locally advanced esophageal cancer. About 44 adults with resectable esophageal squamous cell carcinoma will receive this pre-surgery regimen, followed by surgery to remove the tumor. The main goal is to see how many patients have no cancer cells left in the removed tissue, which could point to a more effective treatment strategy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- A combination of two immunotherapies (ipilimumab and sintilimab) plus chemotherapy and radiation given before surgery
- What this could lead to
- If successful, this approach could increase the chance of eliminating all cancer cells before surgery, potentially improving long-term outcomes for esophageal cancer patients.
- What could go wrong
- This is an early-phase trial with a small number of patients, so results may not be conclusive. Combining multiple treatments can increase side effects, and the approach may not work for everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
No.651 Dongfeng East Road,Guangzhou
RECRUITINGGuangzhou, Guangdong, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an AI eye guide surgeons to safer, faster cancer removal?
- Can early tumor response guide smarter cancer treatment?
- Could a smart combo of drugs and radiation help some esophageal cancer patients skip surgery?
- Could more surgery and radiation after immunotherapy keep esophageal cancer at bay?
- Blood and tissue markers could forecast esophageal cancer return
- Two-Drug cocktail aims to shrink Hard-to-Treat esophageal and stomach tumors